Drug News

Stay up-to-date on the latest drug news. Learn about new drug approvals, labeling changes, expanded indications, recalls, and approvals of generic formulations. These drug news updates are compiled from the latest information from Facts & Comparisons® and the U.S. Food and Drug Administration.

(Updated February 16, 2018)

The FDA has approved the following drugss:
  • Erleada (apalutamide) oral tablets to treat patients with non-metastatic, castration-resistant prostate cancer.
  • Symdeko (tezacaftor/ivacaftor and ivacaftor) oral tablets to treat patients 12 years and older with cystic fibrosis who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.
The FDA has approved the following expanded indications:
  • Zytiga (abiraterone acetate) oral tablets to treat, in combination with prednisone, metastatic high-risk castration-sensitive prostate cancer. Zytiga is also approved in combination with prednisone to treat metastatic castration-resistant prostate cancer.
 

More Nursing News Headlines (Pharmacy)...

Powered by